Scott T. Tagawa, MD, MS, FACP, Weill Cornell Medicine, New York City, NY, provides an overview of an ongoing Phase III study named PSMAddition (NCT04720157) which aims to compare treatment with 177Lu-PSMA-617 plus standard of care (SOC) versus standard of care alone in patients with metastatic hormone-sensitive prostate cancer. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.